Compare TTEK & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | HALO |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.1B |
| IPO Year | 1995 | 2001 |
| Metric | TTEK | HALO |
|---|---|---|
| Price | $33.83 | $82.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $44.00 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.18 | ★ 1.22 |
| Revenue | ★ $2,964,148,000.00 | $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $6.43 | $12.56 |
| P/E Ratio | ★ $43.63 | $67.66 |
| Revenue Growth | ★ 7.66 | N/A |
| 52 Week Low | $25.81 | $59.38 |
| 52 Week High | $43.14 | $84.44 |
| Indicator | TTEK | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 65.07 |
| Support Level | $32.77 | $67.63 |
| Resistance Level | $34.82 | N/A |
| Average True Range (ATR) | 1.15 | 2.15 |
| MACD | 0.16 | 0.15 |
| Stochastic Oscillator | 76.04 | 82.56 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.